For the first time, researchers have shown how a class of advanced prostate cancer drugs are processed in the body and how their anti-tumor activity might change depending on how they are metabolized. Their pre-clinical findings may lay the foundation for improving therapies for treatment-resistant, aggressive prostate cancer.